Prescribing overview
A canine emetic; the reviewed product is UK-authorized Apovomin, not evidence of US animal approval.
Professional assessment of the swallowed substance and aspiration risk determines whether vomiting is appropriate.
Key prescribing checks
- Read the product-specific safety section and monitoring plan before selecting a treatment.
Uses by species
Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.
Dogs
UK veterinary product label; US approval not established hereInduction of emesis
Dogs only in this reviewed scope.
Use / indication source ↗Pharmacology & pharmacokinetics
Mechanism and clinical role
Stimulates dopamine D2 receptors in the chemoreceptor trigger zone.
Absorption, distribution, metabolism and elimination
Rapid subcutaneous absorption; hepatic metabolism with urinary excretion of metabolites.
SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC
Contraindications & cautions
Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.
Apovomin
UK veterinary product label; US approval not established here; 1 mg/mL solution for subcutaneous injection (UK product).
Contraindications · when not to use
- CNS depression, impaired airway reflexes, major neurologic compromise, shock or anesthesia; corrosives, foaming/volatile products, solvents or sharp objects.
- Hypersensitivity or dopamine-antagonist treatment within the preceding 24 hours.
Precautions & monitoring
- Assess severe hepatic disease and reproductive risks. Do not repeat an ineffective injection.
Selected product scope; does not establish suitability for other species, routes or formulations.
Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.
Adverse effects
Drowsiness, reduced appetite, salivation, injection pain, dehydration and cardiovascular changes can occur.
These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.
Dosing & administration
A verified veterinary dose has not been entered for this product. Human-label dosing must not be used as an animal regimen. Consult a current species-specific clinical source and the prescribing veterinarian.
No numeric regimen is supplied in this reference. The veterinarian must select the exact product-label protocol for the patient, indication and route; this entry does not enable an automatic dose.
Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗
Drug & supplement interactions
This monograph summarizes selected interactions. The comparison tool applies a curated set of rules and is not comprehensive. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.
Compare with other medications and check species →
Apovomin
UK veterinary product label; US approval not established here; 1 mg/mL solution for subcutaneous injection (UK product).
- Dopamine antagonists suppress emesis; opioids and barbiturates can add CNS/respiratory depression.
Monitoring
Assess airway protection, respiration, circulation and persistent vomiting.
Client counseling
Do not attempt home emesis with this injection. Give the emergency team the exposure details.
This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.
Storage & handling
UK 1 mg/mL product: refrigerate, protect from light, and discard 28 days after opening.
Brands, formulations & ingredient identity
Active ingredients
Apomorphine hydrochloride hemihydrate
Apovomin is a UK brand association. US product, compounding and prescribing requirements require separate review.
Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.
Apovomin
- Formulation
- 1 mg/mL solution for subcutaneous injection (UK product)
- Label / product scope
- Dogs
Dogs only in this reviewed scope.
Product label / source ↗References & review status
Clinical reference updated October 27, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.
Search another medication or supplement →